Efficacy of intrathecally administered dexmedetomidine versus dexmedetomidine with fentanyl in patients undergoing major abdominal cancer surgery
Most of the clinical experience gained in the use of intrathecal alpha-2- adrenoceptor agonists has been described with clonidine. Human studies using a combination of intrathecal dexmedetomidine and local anesthetics are lacking. A safety investigation and comparison of the analgesic efficacy of in...
Gespeichert in:
| Veröffentlicht in: | Pain physician 2012-07, Vol.15 (4), p.339-348 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 348 |
|---|---|
| container_issue | 4 |
| container_start_page | 339 |
| container_title | Pain physician |
| container_volume | 15 |
| creator | Mohamed, Ashraf Amin Fares, Khaled Mohamed Mohamed, Sahar Abd-Elbaky |
| description | Most of the clinical experience gained in the use of intrathecal alpha-2- adrenoceptor agonists has been described with clonidine. Human studies using a combination of intrathecal dexmedetomidine and local anesthetics are lacking.
A safety investigation and comparison of the analgesic efficacy of intrathecally administered dexmedetomidine or dexmedetomidine combined with fentanyl in patients undergoing major abdominal cancer surgery.
A randomized, double-blind trial.
Academic medical center.
Ninety patients were randomly assigned to receive intrathecally either 10 mg bupivacaine 0.5% (control group, n = 30), or 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine (dexmedetomidine group, n = 30), or 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine and 25 μg fentanyl (dexmedetomidine= group, n = 30). Assessment parameters included hemodynamics, sedation score, pain severity, time of first analgesics request, total analgesic consumption, and side effects in the first 24 hours.
The mean intraoperative heart rate was significantly reduced in the dexmedetomidine group (P < 0.05) and the dexmedetomidine= group (P < 0.05) compared with the control group. Also, there was a significant reduction in mean intraoperative systolic and diastolic blood pressure in the dexmedetomidine group (P < 0.05) and the dexmedetomidine= group (P < 0.05) compared with the control group, with no significant differences in postoperative hemodynamics or sedation scores among all the study groups. The mean visual analog scale scores showed a significant reduction immediately and at 12 hours postoperatively in both the dexmedetomidine and dexmedetomidine= groups compared to the control group. The mean time of the first analgesic request was significantly prolonged in the dexmedetomidine group (3.30 ± 0.87 hours, P < 0.01) and the dexmedetomidine= group (5.41 ± 1.23 hours, P < 0.01) compared with the control group (0.23 ± 0.11 hours). Moreover, postoperative tramadol consumption was significantly reduced in the dexmedetomidine (142.85 ± 13.04 mg, P < 0.01) and the dexmedetomidine= (131.25 ± 11.96 mg, P < 0.01) groups, compared with the control group (310.0 ± 12.08 mg). No significant serious adverse effects were recorded during the study.
This study is limited by its sample size.
Dexmedetomidine 5 μg given intrathecally improves the quality and the duration of postoperative analgesia and also provides an analgesic sparing effect in patients undergoing major abdominal cancer surgery. Furthermore |
| doi_str_mv | 10.36076/ppj.2012/15/339 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1028017088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1028017088</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-f4492d4e161c5c0856b88d2164895be7562c4fedd593ef4cbc17079ffc108d783</originalsourceid><addsrcrecordid>eNplkUtv1TAQhS0EopeWPStkiQ2b9PoRO_YSVYUiVeqGri3HHt_6KnGCnQD5Gfxj3Acs6Go0o3OOZuZD6B0l51ySTu7n-XjOCGV7Kvac6xdox6ggDaWtfol2VHDecCr0CXpTypEQLrXmr9EJY4opqdQO_b4MITrrNjwFHNOS7XIHzg7Dhq0fY4plgQwee_g1godlGqOPCfAPyGUtz8Y_43KHA6TFpm2oeXi2S6xtwWvykA9TTAc82uOUse19dSU7YGeTg4zLmg-QtzP0KtihwNuneopuP19-u7hqrm--fL34dN24esXShLbVzLdAJXXCESVkr5RnVLZKix46IZlrA3gvNIfQut7RjnQ6BEeJ8p3ip-jjY-6cp-8rlMWMsTgYBptgWouhhClSPepe-uE_6XFac129GCaF0FoxxquKPKpcnkrJEMyc42jzVqPMAy5TcZl7XIYKU3FVy_un4LWvf_xn-MuH_wFXjJTZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2655998223</pqid></control><display><type>article</type><title>Efficacy of intrathecally administered dexmedetomidine versus dexmedetomidine with fentanyl in patients undergoing major abdominal cancer surgery</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mohamed, Ashraf Amin ; Fares, Khaled Mohamed ; Mohamed, Sahar Abd-Elbaky</creator><creatorcontrib>Mohamed, Ashraf Amin ; Fares, Khaled Mohamed ; Mohamed, Sahar Abd-Elbaky</creatorcontrib><description><![CDATA[Most of the clinical experience gained in the use of intrathecal alpha-2- adrenoceptor agonists has been described with clonidine. Human studies using a combination of intrathecal dexmedetomidine and local anesthetics are lacking.
A safety investigation and comparison of the analgesic efficacy of intrathecally administered dexmedetomidine or dexmedetomidine combined with fentanyl in patients undergoing major abdominal cancer surgery.
A randomized, double-blind trial.
Academic medical center.
Ninety patients were randomly assigned to receive intrathecally either 10 mg bupivacaine 0.5% (control group, n = 30), or 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine (dexmedetomidine group, n = 30), or 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine and 25 μg fentanyl (dexmedetomidine= group, n = 30). Assessment parameters included hemodynamics, sedation score, pain severity, time of first analgesics request, total analgesic consumption, and side effects in the first 24 hours.
The mean intraoperative heart rate was significantly reduced in the dexmedetomidine group (P < 0.05) and the dexmedetomidine= group (P < 0.05) compared with the control group. Also, there was a significant reduction in mean intraoperative systolic and diastolic blood pressure in the dexmedetomidine group (P < 0.05) and the dexmedetomidine= group (P < 0.05) compared with the control group, with no significant differences in postoperative hemodynamics or sedation scores among all the study groups. The mean visual analog scale scores showed a significant reduction immediately and at 12 hours postoperatively in both the dexmedetomidine and dexmedetomidine= groups compared to the control group. The mean time of the first analgesic request was significantly prolonged in the dexmedetomidine group (3.30 ± 0.87 hours, P < 0.01) and the dexmedetomidine= group (5.41 ± 1.23 hours, P < 0.01) compared with the control group (0.23 ± 0.11 hours). Moreover, postoperative tramadol consumption was significantly reduced in the dexmedetomidine (142.85 ± 13.04 mg, P < 0.01) and the dexmedetomidine= (131.25 ± 11.96 mg, P < 0.01) groups, compared with the control group (310.0 ± 12.08 mg). No significant serious adverse effects were recorded during the study.
This study is limited by its sample size.
Dexmedetomidine 5 μg given intrathecally improves the quality and the duration of postoperative analgesia and also provides an analgesic sparing effect in patients undergoing major abdominal cancer surgery. Furthermore, the addition of intrathecal fentanyl 25 μg has no valuable clinical effect.]]></description><identifier>ISSN: 1533-3159</identifier><identifier>EISSN: 2150-1149</identifier><identifier>DOI: 10.36076/ppj.2012/15/339</identifier><identifier>PMID: 22828688</identifier><language>eng</language><publisher>United States: American Society of Interventional Pain Physician</publisher><subject>Abdomen ; Adult ; Analgesics ; Analgesics - administration & dosage ; Analgesics - adverse effects ; Anesthesia ; Cancer surgery ; Dexmedetomidine - administration & dosage ; Dexmedetomidine - adverse effects ; Digestive System Surgical Procedures - adverse effects ; Double-Blind Method ; Drug Therapy, Combination - adverse effects ; Drug Therapy, Combination - methods ; Female ; Fentanyl ; Fentanyl - administration & dosage ; Fentanyl - adverse effects ; Gastric cancer ; Hemodynamics ; Hemodynamics - drug effects ; Humans ; Injections, Spinal ; Male ; Middle Aged ; Pain management ; Pain Management - methods ; Pain Measurement ; Pain, Postoperative - prevention & control ; Stomach Neoplasms - surgery</subject><ispartof>Pain physician, 2012-07, Vol.15 (4), p.339-348</ispartof><rights>2012. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-f4492d4e161c5c0856b88d2164895be7562c4fedd593ef4cbc17079ffc108d783</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22828688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohamed, Ashraf Amin</creatorcontrib><creatorcontrib>Fares, Khaled Mohamed</creatorcontrib><creatorcontrib>Mohamed, Sahar Abd-Elbaky</creatorcontrib><title>Efficacy of intrathecally administered dexmedetomidine versus dexmedetomidine with fentanyl in patients undergoing major abdominal cancer surgery</title><title>Pain physician</title><addtitle>Pain Physician</addtitle><description><![CDATA[Most of the clinical experience gained in the use of intrathecal alpha-2- adrenoceptor agonists has been described with clonidine. Human studies using a combination of intrathecal dexmedetomidine and local anesthetics are lacking.
A safety investigation and comparison of the analgesic efficacy of intrathecally administered dexmedetomidine or dexmedetomidine combined with fentanyl in patients undergoing major abdominal cancer surgery.
A randomized, double-blind trial.
Academic medical center.
Ninety patients were randomly assigned to receive intrathecally either 10 mg bupivacaine 0.5% (control group, n = 30), or 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine (dexmedetomidine group, n = 30), or 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine and 25 μg fentanyl (dexmedetomidine= group, n = 30). Assessment parameters included hemodynamics, sedation score, pain severity, time of first analgesics request, total analgesic consumption, and side effects in the first 24 hours.
The mean intraoperative heart rate was significantly reduced in the dexmedetomidine group (P < 0.05) and the dexmedetomidine= group (P < 0.05) compared with the control group. Also, there was a significant reduction in mean intraoperative systolic and diastolic blood pressure in the dexmedetomidine group (P < 0.05) and the dexmedetomidine= group (P < 0.05) compared with the control group, with no significant differences in postoperative hemodynamics or sedation scores among all the study groups. The mean visual analog scale scores showed a significant reduction immediately and at 12 hours postoperatively in both the dexmedetomidine and dexmedetomidine= groups compared to the control group. The mean time of the first analgesic request was significantly prolonged in the dexmedetomidine group (3.30 ± 0.87 hours, P < 0.01) and the dexmedetomidine= group (5.41 ± 1.23 hours, P < 0.01) compared with the control group (0.23 ± 0.11 hours). Moreover, postoperative tramadol consumption was significantly reduced in the dexmedetomidine (142.85 ± 13.04 mg, P < 0.01) and the dexmedetomidine= (131.25 ± 11.96 mg, P < 0.01) groups, compared with the control group (310.0 ± 12.08 mg). No significant serious adverse effects were recorded during the study.
This study is limited by its sample size.
Dexmedetomidine 5 μg given intrathecally improves the quality and the duration of postoperative analgesia and also provides an analgesic sparing effect in patients undergoing major abdominal cancer surgery. Furthermore, the addition of intrathecal fentanyl 25 μg has no valuable clinical effect.]]></description><subject>Abdomen</subject><subject>Adult</subject><subject>Analgesics</subject><subject>Analgesics - administration & dosage</subject><subject>Analgesics - adverse effects</subject><subject>Anesthesia</subject><subject>Cancer surgery</subject><subject>Dexmedetomidine - administration & dosage</subject><subject>Dexmedetomidine - adverse effects</subject><subject>Digestive System Surgical Procedures - adverse effects</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Drug Therapy, Combination - methods</subject><subject>Female</subject><subject>Fentanyl</subject><subject>Fentanyl - administration & dosage</subject><subject>Fentanyl - adverse effects</subject><subject>Gastric cancer</subject><subject>Hemodynamics</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Injections, Spinal</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pain management</subject><subject>Pain Management - methods</subject><subject>Pain Measurement</subject><subject>Pain, Postoperative - prevention & control</subject><subject>Stomach Neoplasms - surgery</subject><issn>1533-3159</issn><issn>2150-1149</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNplkUtv1TAQhS0EopeWPStkiQ2b9PoRO_YSVYUiVeqGri3HHt_6KnGCnQD5Gfxj3Acs6Go0o3OOZuZD6B0l51ySTu7n-XjOCGV7Kvac6xdox6ggDaWtfol2VHDecCr0CXpTypEQLrXmr9EJY4opqdQO_b4MITrrNjwFHNOS7XIHzg7Dhq0fY4plgQwee_g1godlGqOPCfAPyGUtz8Y_43KHA6TFpm2oeXi2S6xtwWvykA9TTAc82uOUse19dSU7YGeTg4zLmg-QtzP0KtihwNuneopuP19-u7hqrm--fL34dN24esXShLbVzLdAJXXCESVkr5RnVLZKix46IZlrA3gvNIfQut7RjnQ6BEeJ8p3ip-jjY-6cp-8rlMWMsTgYBptgWouhhClSPepe-uE_6XFac129GCaF0FoxxquKPKpcnkrJEMyc42jzVqPMAy5TcZl7XIYKU3FVy_un4LWvf_xn-MuH_wFXjJTZ</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Mohamed, Ashraf Amin</creator><creator>Fares, Khaled Mohamed</creator><creator>Mohamed, Sahar Abd-Elbaky</creator><general>American Society of Interventional Pain Physician</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Efficacy of intrathecally administered dexmedetomidine versus dexmedetomidine with fentanyl in patients undergoing major abdominal cancer surgery</title><author>Mohamed, Ashraf Amin ; Fares, Khaled Mohamed ; Mohamed, Sahar Abd-Elbaky</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-f4492d4e161c5c0856b88d2164895be7562c4fedd593ef4cbc17079ffc108d783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abdomen</topic><topic>Adult</topic><topic>Analgesics</topic><topic>Analgesics - administration & dosage</topic><topic>Analgesics - adverse effects</topic><topic>Anesthesia</topic><topic>Cancer surgery</topic><topic>Dexmedetomidine - administration & dosage</topic><topic>Dexmedetomidine - adverse effects</topic><topic>Digestive System Surgical Procedures - adverse effects</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Drug Therapy, Combination - methods</topic><topic>Female</topic><topic>Fentanyl</topic><topic>Fentanyl - administration & dosage</topic><topic>Fentanyl - adverse effects</topic><topic>Gastric cancer</topic><topic>Hemodynamics</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Injections, Spinal</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pain management</topic><topic>Pain Management - methods</topic><topic>Pain Measurement</topic><topic>Pain, Postoperative - prevention & control</topic><topic>Stomach Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohamed, Ashraf Amin</creatorcontrib><creatorcontrib>Fares, Khaled Mohamed</creatorcontrib><creatorcontrib>Mohamed, Sahar Abd-Elbaky</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pain physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohamed, Ashraf Amin</au><au>Fares, Khaled Mohamed</au><au>Mohamed, Sahar Abd-Elbaky</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of intrathecally administered dexmedetomidine versus dexmedetomidine with fentanyl in patients undergoing major abdominal cancer surgery</atitle><jtitle>Pain physician</jtitle><addtitle>Pain Physician</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>15</volume><issue>4</issue><spage>339</spage><epage>348</epage><pages>339-348</pages><issn>1533-3159</issn><eissn>2150-1149</eissn><abstract><![CDATA[Most of the clinical experience gained in the use of intrathecal alpha-2- adrenoceptor agonists has been described with clonidine. Human studies using a combination of intrathecal dexmedetomidine and local anesthetics are lacking.
A safety investigation and comparison of the analgesic efficacy of intrathecally administered dexmedetomidine or dexmedetomidine combined with fentanyl in patients undergoing major abdominal cancer surgery.
A randomized, double-blind trial.
Academic medical center.
Ninety patients were randomly assigned to receive intrathecally either 10 mg bupivacaine 0.5% (control group, n = 30), or 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine (dexmedetomidine group, n = 30), or 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine and 25 μg fentanyl (dexmedetomidine= group, n = 30). Assessment parameters included hemodynamics, sedation score, pain severity, time of first analgesics request, total analgesic consumption, and side effects in the first 24 hours.
The mean intraoperative heart rate was significantly reduced in the dexmedetomidine group (P < 0.05) and the dexmedetomidine= group (P < 0.05) compared with the control group. Also, there was a significant reduction in mean intraoperative systolic and diastolic blood pressure in the dexmedetomidine group (P < 0.05) and the dexmedetomidine= group (P < 0.05) compared with the control group, with no significant differences in postoperative hemodynamics or sedation scores among all the study groups. The mean visual analog scale scores showed a significant reduction immediately and at 12 hours postoperatively in both the dexmedetomidine and dexmedetomidine= groups compared to the control group. The mean time of the first analgesic request was significantly prolonged in the dexmedetomidine group (3.30 ± 0.87 hours, P < 0.01) and the dexmedetomidine= group (5.41 ± 1.23 hours, P < 0.01) compared with the control group (0.23 ± 0.11 hours). Moreover, postoperative tramadol consumption was significantly reduced in the dexmedetomidine (142.85 ± 13.04 mg, P < 0.01) and the dexmedetomidine= (131.25 ± 11.96 mg, P < 0.01) groups, compared with the control group (310.0 ± 12.08 mg). No significant serious adverse effects were recorded during the study.
This study is limited by its sample size.
Dexmedetomidine 5 μg given intrathecally improves the quality and the duration of postoperative analgesia and also provides an analgesic sparing effect in patients undergoing major abdominal cancer surgery. Furthermore, the addition of intrathecal fentanyl 25 μg has no valuable clinical effect.]]></abstract><cop>United States</cop><pub>American Society of Interventional Pain Physician</pub><pmid>22828688</pmid><doi>10.36076/ppj.2012/15/339</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1533-3159 |
| ispartof | Pain physician, 2012-07, Vol.15 (4), p.339-348 |
| issn | 1533-3159 2150-1149 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1028017088 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Abdomen Adult Analgesics Analgesics - administration & dosage Analgesics - adverse effects Anesthesia Cancer surgery Dexmedetomidine - administration & dosage Dexmedetomidine - adverse effects Digestive System Surgical Procedures - adverse effects Double-Blind Method Drug Therapy, Combination - adverse effects Drug Therapy, Combination - methods Female Fentanyl Fentanyl - administration & dosage Fentanyl - adverse effects Gastric cancer Hemodynamics Hemodynamics - drug effects Humans Injections, Spinal Male Middle Aged Pain management Pain Management - methods Pain Measurement Pain, Postoperative - prevention & control Stomach Neoplasms - surgery |
| title | Efficacy of intrathecally administered dexmedetomidine versus dexmedetomidine with fentanyl in patients undergoing major abdominal cancer surgery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A39%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20intrathecally%20administered%20dexmedetomidine%20versus%20dexmedetomidine%20with%20fentanyl%20in%20patients%20undergoing%20major%20abdominal%20cancer%20surgery&rft.jtitle=Pain%20physician&rft.au=Mohamed,%20Ashraf%20Amin&rft.date=2012-07-01&rft.volume=15&rft.issue=4&rft.spage=339&rft.epage=348&rft.pages=339-348&rft.issn=1533-3159&rft.eissn=2150-1149&rft_id=info:doi/10.36076/ppj.2012/15/339&rft_dat=%3Cproquest_cross%3E1028017088%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2655998223&rft_id=info:pmid/22828688&rfr_iscdi=true |